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S U M M A R Y
B A C K G R O U N D : Post-TB lung disease (PTLD) is an
important but under-recognised chronic respiratory
disease in high TB burden settings such as Tanzania.
M E T H O D S : This was a cross-sectional survey of adults
within 2 years of completion of TB treatment in
Kilimanjaro, Tanzania. Data were collected using
questionnaires (symptoms and exposures), spirometry
and chest radiographs to assess outcome measures,
which were correlated with daily life exposures,
including environment and diet.
R E S U LT S : Of the 219 participants enrolled (mean
age: 45 years 6 10; 193 [88%] males), 98 (45%)
reported chronic respiratory symptoms; 46 (22%)
had received treatment for TB two or more times;
and HIV prevalence was 35 (16%). Spirometric
abnormalities were observed in 146 (67%). Chest
X-ray abnormalities occurred in 177 (86%). A
diagnosis of PTLD was made in 200 (91%), and half
had clinically relevant PTLD. The prevalence of
mMRC Grade 3 chronic bronchitis and dyspnoea
was respectively 11% and 26%. Older age, multiple
episodes of TB and poverty indicators were linked
with clinically relevant PTLD.
C O N C L U S I O N S : We found a substantial burden of
PTLD in adults who had recently completed TB
treatment in Tanzania. There is a pressing need to
identify effective approaches for both the prevention and
management of this disease.
K E Y W O R D S : post-tuberculosis; spirometry; mixed-
pattern; radiographs; obstruction
Although appropriate pulmonary TB (PTB) treatment
can achieve microbial cure, the burden of ill health
after TB, including post-TB lung disease (PTLD) is
now increasingly recognised.1 People with PTLD have
reduced health-related quality of life and reduced
exercise tolerance.2 Even the successful completion of
PTB treatment confers a 3.76 times higher risk of
death than in the general population.3 PTLD contrib-
utes to the burden of chronic respiratory disease
(CRD) in children and adults in high TB settings; in
sub-Saharan Africa, there is a substantial burden of
CRD, with an estimated 4.5–5.8% of the population
affected.4,5
Health systems in sub-Saharan Africa treat and
cure 2–2.5 million people with PTB every year.6
Typically, there is no assessment of health and
wellbeing beyond a narrow classification of ‘‘treat-
ment outcome’’, and no services targeted at long-term
post-TB health needs.7 A poor understanding of the
health and wellbeing needs of this patient group
contributes to this lack of health service provision.8
In Tanzania, 60,000–75,000 people have been
treated for PTB annually in recent decades,9 with
high short-term treatment success. However, comor-
bidities are frequent among PTB patients: 25–40%
have human immunodeficiency virus (HIV) co-
infection and 16% suffer from diabetes.10,11 PTB
also directly contributes to poor lung function due to
parenchymal destruction, interstitial lung disease,
loss of alveolar surfaces and primary vascular
processes, culminating in patients with complex
medical needs.12,13 Additional insults, such as tobac-
co smoking, household and outdoor air pollution,
and exposure to dust, gases or fumes independently
cause CRD.14 It is not clear how these CRD risk
factors interact with or alter the severity of PTLD.
In the present study, we investigated the burden
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and severity of PTLD, and the relationship between




The Kibong’oto Infectious Diseases Hospital (KIDH)
in Kilimanjaro Region, Tanzania, is a national
referral hospital specialising in TB/multidrug-resis-
tant TB (MDR-TB).15 The hospital receives more
than 30,000 patients annually, of whom around
1,000 are diagnosed with TB/MDR-TB and 4,500
present with respiratory diseases other than TB.16
Design
We performed a cross-sectional study of adults who
had been treated at KIDH for at least one episode of
bacteriologically positive drug-susceptible PTB in the
past 2 years. Exclusion criteria were active PTB as
assessed by the standard national algorithm;17 other
serious active health conditions such as malignancy,
dementia, pregnancy; and contraindication or inabil-
ity to do spirometry. All participants provided written
informed consent.
Recruitment
Individuals were identified either from those seeking
care at the outpatient department, or through the
health facility TB unit register where phone contacts
were recorded. Participants were sequentially identi-
fied and invited to take part. Those refusing or
untraceable by phone were not included.
Sample size
A total sample size of 224 was calculated to estimate
the prevalence of PTLD diagnosed based on spiro-
metric abnormalities with 95% confidence intervals
(CIs) and a desired precision of 2.5% (i.e., 62.5%),
assuming a prevalence of 9%.18
Data collection and measurements
A team of clinicians and nurses with knowledge and
experience of at least 2 years on research and lung
disease management received a 2-day protocol
training prior to starting participants enrolment.
Clinicians and nurses conducted interviews of partic-
ipants and documented the responses using standard-
ised data collection questionnaires designed by the
International Multidisciplinary Programme to Ad-
dress Lung Health and TB in Africa (IMPALA)
network.19 The questionnaires collected data on
demographics, symptoms, history of episodes of TB,
in-house and or occupational exposures, cigarette
smoking status and nutrition (https://github.com/
jipp3r/IMPALA_QuestionSet).19 Risk factors for
non-TB CRD were sought to contextualise the data,
and included a first-degree relative with asthma,
history of smoking .10 pack years and relevant
infections such as documented previous pertussis,
measles or adenovirus requiring hospitalisation,
recurrent (2 episodes) non-specified childhood
respiratory infections necessitating hospitalisation
or HIV co-infection.
Spirometric data were collected using the Easy-
Onew Spirometer (ndd, Zurich, Switzerland) accord-
ing to American Thoracic Society and European
Respiratory Society (ATS/ERS) standards.20 Research
staff explained and demonstrated the procedure to
the research participant. Measurements were carried
out as described elsewhere, and included at least three
acceptable and repeatable forced vital capacity (FVC)
manoeuvres performed both before and after inhaled
bronchodilator (salbutamol 200 lg via metered-dose
inhaler).21 Clinical data included forced expiratory
volume in 1 sec (FEV1), FVC and the ratio (FEV1/
FVC). The 2012 Global Lung Function Initiative
reference equations adjusted for non-Caucasian
patients were used.22 The best values for FVC and
for FEV1 were classified and reported.21 Severity of
FEV1 reductions were described using ATS/ERS
classifications of FEV1 percentage of predicted as
follows: mild (70–79%), moderate (60–69%), mod-
erate-severe (50–59%), severe (35–49%) and very
severe (,35%).21 Chest X-ray was performed and
reported by a radiologist.
Definition of post-TB lung disease
PTLD is defined as evidence of chronic respiratory
abnormality, with or without symptoms, attributable
at least in part to previous PTB.7 Clinically relevant
PTLD was defined as the presence of respiratory
symptoms that were most likely attributable to
previous PTB, and not better explained by any other
respiratory condition (e.g., asthma or chronic ob-
structive pulmonary disease) preceding PTB diagno-
sis. The respiratory symptoms of interest included 1)
cough on most days for 3 months of the year in 2
consecutive years (chronic bronchitis), or cough on
most days since completion of TB treatment; 2)
dyspnoea using the modified Medical Research
Council (mMRC) dyspnoea scale;23 and 3) wheeze
of one or more episodes in the last year.
Bias, data management and quality control
All the questionnaires were reviewed for complete-
ness and accuracy. Spirometry quality assurance
included training and competence assessment of
operators, daily calibration check with a 3L syringe
and assessment of spirograms for acceptability,
reproducibility and repeatability. After review by an
experienced assessor, the best acceptable values were
selected for analysis. Data were double-entered in MS
Access@2018 (Microsoft, Redmond, WA, USA) by
independent data officers, and inconsistencies were
resolved by inspection of source documents.
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Data analysis and statistical methods
PTLD outcomes, daily life exposures and important
confounding variables were described in terms of
frequency (percentage) and mean with 95% CIs or
median with interquartile ranges (IQRs), as appro-
priate. Association between PTLD outcomes and
variables was estimated using one-way analysis of
variance or v2. Odds ratios (ORs) were used to
estimate the association between PTLD and daily life
exposures. Univariable and multivariable logistic
regression models were used to estimate associations
between potential risk factors and symptomatic
PTLD, presented as ORs with 95% CIs. Multivari-
able models were built by using stepwise regression to
select variables. Missing data were treated using
listwise deletion. Variables were retained if statisti-
cally significant (P , 0.05).
Ethical consideration
The study was approved by the KIDH, Kilimanjaro,
Tanzania, the National Ethical Review Boards in
Tanzania (reference no. NIMR/HQ/R.8a/Vol. IX/
2886) and the Liverpool School of Tropical Medicine,
Liverpool, UK (ref 18-047).
RESULTS
Demographics and clinical characteristics
Of the 655 participants treated for bacteriologically
positive PTB during the preceding 2 years, 235 (36%)
could be contacted for inclusion in the study between
October 2018 through April 2020. Of these, 16 (7%)
were excluded and 219 participated and provided
data for analysis (Figure 1). Demographics data such
as age, sex, medical history such as HIV status,
episodes of TB treatment and various environmental
exposures are given in Table 1. None of the
participants had a history of whooping cough or
measles. Spirometry abnormalities occurred in 146
(67%), but all patients with abnormality had
obstruction and 88 (60%) did not respond to
bronchodilators. Most had superimposed low FVC
(n ¼118, 81%), followed by those with only
obstructive pattern (n ¼ 28, 19%); none had only a
restrictive pattern of disease. Severity of abnormal
spirometry of the FEV1% predicted in participants
were ranked mild (n ¼ 37, 25%), moderate (n ¼ 41,
28%), moderate–severe (n¼31, 21%), severe (n¼30,
21%) and very severe (n¼ 7, 5%).
Chest X-ray abnormalities were observed in 177
(86%), most of whom had bilateral changes (n¼133,
75%). Chronic respiratory symptoms were reported
by 98 (45%) participants. Only 96 (45%) smoked
tobacco, and 46 (22) smoked cannabis. Approxi-
mately half the participants had a regular salaried job
(n ¼ 123, 56%), while 142 (65%) had earned
additional money or produced goods for exchange
(Table 1).
Chronic respiratory symptoms
Cough, dyspnoea and wheeze occurred in respectively
60 (27%), 55 (25%) and 43 (20%) participants.
These clinical features commonly co-existed (Figure
2A). Of those reporting cough, 34 (57%) were
affected on most days since treatment completion,
and 25 (42%) met the definition of chronic bronchi-
tis. The median duration of cough was 1.75 years
(IQR 1–3). Cough was associated with phlegm
Figure 1 Recruitment process of study participants. PTB¼ pulmonary TB.
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production in 53 (95%), with 38 (72%) reporting
phlegm on most days and 22 (42%) worse when lying
in a certain position. Distribution of 55 participants
with dyspnoea according to Grades I, II, III and IV of
the mMRC scale was respectively 10 (18%), 9 (16%),
15 (27%) and 21(39%). Of participants reporting
wheeze, 16 (39%) experienced severe attacks (enough
to limit speech to only one or two words at a time
between breaths). The median number of wheezing
attacks, coupled with sleep disturbances was respec-
tively 3 (IQR 2–6) and 3 (IQR 2–4).
Participants meeting the PTLD definition
Overall, most participants met the definition for
PTLD (n ¼ 200, 91%); 92 (42%) had associated
respiratory symptoms (Figure 2B).








n (%) P value
Demographics
Age, years, mean 6 SD 45 6 10 47 6 9 43 6 10 0.004
Male sex 193 (88) 83 (43) 110 (57) 0.547
HIV infection 35 (16) 11 (31) 24 (69) 0.231
TB episodes*
Once 167 (79) 58 (35) 109 (65) 0.001
Twice 43 (20) 27 (63) 16 (37)
More than twice 3 (1) 2 (67) 1(33)
Smoking*
Tobacco 103 (47) 55 (53) 48 (47) 0.002
Cannabis 46 (22) 23 (50) 23 (50) 0.193
Waterpipe 3 (1) 3 (100) 0 (0) 0.065
Source of energy
Cooking†
1–2 stoves 155 (79) 59 (38) 96 (62) 0.041
3–4 stoves 40 (21) 23 (58) 17 (42)
Main user of the cooker (cooker used on most days) 60 (27) 18 (28) 42 (72) 0.039
Number of cooking years, median [IQR] 10 [3–20] 7 [4–14] 10 [3–20] 0.967
House has heating 41 (24) 8 (20) 33 (80) 0.001
House has electric lighting 202 (96) 85 (42) 117 (58) 0.086
Ventilation in cooking area
Closed room 2 (1) 0 (0) 2 (100) 0.899
Room with eaves spaces 5 (2.5) 2 (40) 3 (60)
Room with open windows/doors 203 (96) 84 (41) 119 (59)
Room with ,4 walls 1 (0.5) 0 (0) 1 (100)
Life exposure
Second-hand tobacco smoke in household 40 (19) 19 (47) 21(53) 0.45
Second-hand tobacco smoke in workplace 105 (49) 48 (46) 57 (54) 0.209
Has domestic animals 150 (70) 63 (42) 87 (58) 0.739
Place of residence
Town or city 42 (20) 13 (31) 29 (69) 0.33
Sub-urban 108 (50) 46 (43) 62 (57)
Rural 65 (30) 29 (45) 36 (55)
Time lived in town/city, years, median [IQR] 12 [6–20] 16 [8–24] 10 [6–18] 0.024
Time lived in village, years, median [IQR] 20 [13–29] 19 [14–32] 20 [10–28] 0.669
Traffic exposure
Distance from home to major road (with lorries or regular buses/minibuses), m
,100 93 (43) 32 (34) 61(66) 0.188
100–500 57 (27) 28 (49) 29 (51)
.500 65 (30) 28 (43) 37 (57)
Traffic density on closest major road
.10 per min 60 (28) 26 (43) 34 (57) 0.101
1–10 per min 95 (45) 31 (33) 64 (67)
1 every 1–10 min 29 (14) 16 (55) 13 (45)
,1 every 10 min 28 (13) 14 (50) 14 (50)
Social history
Drinks alcohol 125 (59) 59 (47) 66 (53) 0.046
Beer, bottles/week, median [IQR] 14 [3–21] 14 [5–21] 10 [2–21] 0.485
Wine, glasses/week, median [IQR] 7 [2–25] 2 [1–7] 17 [4–24] 0.378
Spirits, shots/week, median [IQR] 15 [5–17] 16 [7–45] 16 [7–45] 0.285
Local brew, bottles/week, median [IQR] 10 [4–20] 13 [5–21] 12 [4–20] 0.739
Regular paid work 123 (57) 38 (31) 85 (69) 0.001
Other work or producing goods for exchange 142 (66) 49 (35) 93 (65) 0.009
* 6 participants had missing responses.
† 24 participants had no history of cooking.
PTLD¼ pulmonary TB lung disease; SD¼ standard deviation; IQR¼ interquartile range.
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Exposures to potential risk factors
The median number of cigarettes smoked per day was
8 (IQR 4–20), with a median age of starting and
stopping smoking of 20 years (IQR 17–25) and 38
years (IQR 36–40) respectively. Tobacco smoking
increased symptomatic presentation of PTLD in 55
(53%) compared to non-smokers in 37 (32%; P ¼
0.002). Individuals cooking with 3–4 stoves com-
pared to 1–2 stoves had increased symptomatic PTLD
(respectively n¼23, 58% vs. n¼59, 38%; P¼0.041).
Individuals who did not heat their houses at any time
developed more symptomatic PTLD than those who
did (n ¼ 67, 52% vs. n ¼ 8, 20%; P ¼ 0.001).
Symptomatic PTLD was associated with living many
years in urban areas (median 16 years, IQR 8–24 vs.
10 years, IQR 6–18) in the asymptomatic group,
regardless of PTLD status (P¼ 0.024); alcohol abuse
was also more likely to be associated with PTLD
symptoms compared to those who did not consume
alcohol (n¼59, 47% vs. n¼28, 33%; P¼0.046). We
found that various ambient air pollution exposures
such as methods of household lighting; modes of
household ventilation; secondary cigarette smoking;
urban, rural or traffic exposures were not significant-
ly associated with PTLD (Table 1).
Forty-two (19%) participants had inadequate food to
have normal meals. Five (100%) individuals with an
average of 1 meal/day, 27 (55%) with at least an
average of 2 meals/day and 55 (35%) with at least three
meals/day were symptomatic (P ¼ 0.001). Food
insecurity, eating cereals, consuming oily food and fruit
juice intake were strongly associated with symptomatic
PTLD (Figure 3) Intake of other food types and varieties
were not correlated with PTLD (Supplementary Data I)
Clinically relevant, symptomatic PTLDs were
associated with advanced age, history of previous
multiple TB retreatment and night sweats, whereas
having a paid job was protective. Sex and HIV
infection were not associated with symptomatic
PTLD (Table 2A). Univariate analysis of diet intake
showed that inadequate food and alcohol consump-
tion significantly increased the odds of symptomatic
PTLD, while intake of cereals, potatoes, pulses, fruits,
fruit juice and bread at least once per week were
negatively associated with PTLD (Table 2A).
Logistic regression models for predicting clinically
relevant PTLD
In univariable logistic regression models, age .35
years, TB retreatment, night sweats, food insecurity,
alcohol intake and tobacco smoking were associated
with an increased odd of symptomatic PTLD, while
having a paid job, being the main cooker user, heating
the house at any time in a year, eating at least 2 meals
per day, particularly meals including bread, fruits or
juices were associated with reduced odds of symp-
tomatic PTLD (Table 2A).
On multivariable logistic regression, age .35
years, TB retreatment, night sweats, tobacco smok-
ing, and eating cereals and oily food more than once a
week were associated with increased odds of symp-
tomatic PTLD. Eating fruits and drinking juice at
least once a week were associated with reduced odds
of developing symptomatic PTLD (Table 2B).
DISCUSSION
PTLD was identified in the majority (91%) of
Tanzanian adults cured of PTB in our study, approx-
imately half of whom had clinically relevant disease.
Chronic cough was the most common symptom, which
often overlapped with wheeze or moderate to severe
dyspnoea. These generally occurred in individuals with
no prior history of CRD, suggesting PTB was the main
trigger of these symptoms and impairment of lung
function, as previously described.24,25 We identified a
number of factors associated with an increased risk of
having clinically relevant PTLD, including older age,
multiple courses of TB treatment and several poverty
indicators.26
Figure 2 A) Proportional area diagram showing reported clinical symptoms of participants. B)
Proportional area diagram showing distribution of post-TB according to respiratory symptoms,
spirometry and chest radiograph results. PTLD¼ pulmonary TB lung disease.
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Figure 3 Association between nutrition and PTLD. Each panel shows the frequency of food/diet intake. PTLD¼pulmonary TB lung
disease.
Table 2A) Estimates of association between individual risk factors for symptomatic PTLD (n¼
92) by univariable logistic regression
Predictor variables OR (95% CI) P value
Male sex 1.4 (0.6–3.5) 0.418
HIV-positive 0.6 (0.3–1.2) 0.170
Age, years
18–34 Reference
35–50 6.7 (2.2–29.1) 0.003
.50 6.3 (1.9–28.6) 0.006
More than 1 episode of TB 3.5 (1.9–6.9) ,0.001
Main cooker user 0.5 (0.3–0.9) 0.029
Heating system in the house 0.3 (0.1–0.5) 0.001
Electricity available 1.5 (0.5–4.9) 0.483
Tobacco smokers 2.4 (1.4–4.3) 0.001
Cannabis smokers 1.5 (0.8–2.9) 0.218
Having a paid job 0.4 (0.2–0.7) 0.001
Night sweat 3.6 (1.4–10.6) 0.012
Eating bread more than once a week 0.4 (0.2–0.7) 0.001
Eating .2 meals per day 0.4 (0.2–0.7) 0.001
Inadequate food 4.3 (2.2–8.9) ,0.001
Eating cereals more than once a week 1.2 (0.7–2.3) 0.498
Eating potatoes more than once a week 0.6 (0.3–1.0) 0.050
Eating pulses more than once a week 1.0 (0.6–1.9) 0.898
Eating porridge more than once a week 1.3 (0.8–2.4) 0.312
Eating fruits more than once a week 0.3 (0.1–0.8) 0.030
Taking juice more than once a week 0.4 (0.2–0.8) 0.004
Eating oily food more than once a week 1.9 (0.8–5.0) 0.182
Eating sweets more than once a week 0.7 (0.7–1.7) 0.459
Alcohol intake 1.8 (1.0–3.2) 0.040
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Our findings of a high burden of chronic cough and
dyspnoea (mMRC Grade 2, 3 and 4) are consistent with
those from recent studies from South Africa; neverthe-
less, all of the South African population studied had a
history of smoking, with respectively 17% and 42%
presenting with phlegm production and wheeze.27 To
note, we observed that HIV did not influence the
clinical presentation of our participants and, this is in
contrast with findings from Malawi, which reports that
HIV-negative individuals presented with more symp-
toms of cough and breathlessness.28 The population
studied included those treated for PTB within 2 years;
the prevalence of mMRC (Grades 3 and 4) dyspnoea,
chronic bronchitis and wheeze was very high, at
respectively 26%, 11%, and 8%. This is a considerable
proportion of individuals with poor health conditions
requiring medical interventions, as the risk of death in,
for example, those with Grade 3 dyspnoea within 5
years is three-fold, and up to 2-fold in those with
chronic bronchitis within a decade.29,30
Although half of individuals were asymptomatic,
respectively 27%, 11% and 56% of this sub-group
had anatomical lesions, impaired lung function and
both. The effect of these abnormalities on long-term
wellbeing is not clear; therefore, it is important to
conduct longitudinal studies to inform policy actions
and guidance.31
This study was adequately powered to estimate the
burden and severity of chronic respiratory symptoms
in individuals who had recently completed TB
treatment. The questionnaires administered (https://
github.com/jipp3r/IMPALA_QuestionSet)19 cap-
tured a wide range of exposure parameters and
provided insight into factors that influence symptom-
atic PTLD. For example, various exposure types such
as smoking tobacco, cannabis and water pipe or
living in a town, city or village were included to
explore exposure to different noxious agents and
their effect on clinically relevant PTLD. While
different types of smoking material were captured
to minimise bias and take into account community
preferences, living in towns, cities or villages reflected
the varying levels of exposure to air pollutions, with
cities carrying the highest burden of ambient air
pollution, followed by towns and villages. Likewise,
several types of foods were included in order to
understand their effect on PTLD.
The study had several limitations: the cross-sectional
design may have led to an underestimation of the
burden and predictive factors of PTLD. As symptomatic
PTLD population were recruited from the outpatient
department, there may have been selection bias, and the
selection of participants who reached the evaluation
stage may have led to survival bias. This may also
explain why we had a large number of patients with
obstructive lung impairment. It is also possible that
interviewees had recall bias. Besides, as CXR is not
adequate to detect all abnormalities with physiological
problems, parenchymal and/or parietal damage of the
lungs may have been underestimated.
In conclusion, we found that the burden of PTLD
in Tanzanian adults who had been cured of PTB was
high. Taken together with other recent studies from
sub-Saharan Africa, it is clear that this is an important
and lifelong disease for many after TB.32 This also
indicates a major unmet need, as there is no pathway
Table 2B) Estimates of adjusted associations between risk factors for symptomatic PTLD (n¼92)
in multivariable logistic regression where variables were selected by stepwise regression
Predictor variables aOR (95% CI) P value
Male sex 0.6 (0.1–2.5) 0.468
HIV-positive 1.1 (0.4–2.9) 0.872
Age, years
18–34 Reference
35–50 7.6 (2.0–43.2) 0.009
.50 5.9 (1.3–36.7) 0.0334
More than 1 episode of TB 2.4 (1.1–5.6) 0.040
Main cooker users 0.5 (0.2–1.3) 0.162
Heating system in the house 0.4 (0.2–1.0) 0.049
Tobacco smoking 2.0 (0.9–4.4) 0.079
Cannabis smokers 0.8 (0.3–2.0) 0.622
Having a paid job 0.5 (0.2–1.2) 0.117
Night sweats 3.5 (1.0–13.9) 0.059
Inadequate food 2.2 (0.8–6.4) 0.124
Eating .2 meals per day 0.5 (0.2–1.2) 0.121
Having cereals more than once a week 2.7 (1.2–6.6) 0.020
Having fruits more than once a week 0.1 (0.0–0.5) 0.012
Having greasy food more than once a week 8.7 (2.2–46.0) 0.004
Taking juice more than once a week 0.6 (0.2–1.3) 0.160
Having sweets more than once a week 0.8 (0.6–1.0) 0.121
Alcohol intake 1.4 (0.6–2.9) 0.426
Multiple variables were included in the model, including sex, HIV status, tobacco smoking, age group, TB episodes, paid
job, having porridge, eating cereals, fruits, oily food, fruits, pulses, alcohol, night sweats, weight changes, cannabis
smoking and staying with a cigarette smoker at a working place.
PTLD¼ pulmonary TB lung disease; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR.
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for the clinical management of PTLD in most TB-
endemic countries, resulting in multiple hospitalisa-
tions and (unnecessary) re-treatment for TB.33,34
Further research and evaluation of potential ap-
proaches to the ongoing care of people with PTLD,
including interventions such as pulmonary rehabili-
tation and smoking cessation, are therefore warrant-
ed.35 There is also a real need to address psychosocial
and socio-economic issues, given the strong links
between PTLD and poverty.36
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R É S U M É
C O N T E X T E : La maladie pulmonaire post-TB (PTLD)
est une maladie respiratoire chronique importante mais
sous-identifiée dans les régions à forte incidence de TB
comme la Tanzanie.
M É T H O D E S : Ceci est étude transversale réalisée auprès
d’adultes dans les 2 années suivant la fin de leur
traitement antituberculeux, au Kilimandjaro, Tanzanie.
Les données ont été recueillies par questionnaires
(symptômes et expositions), spirométrie et
radiographies pulmonaires. Elles ont été utilisées pour
évaluer les mesures de résultats et ont été corrélées avec
les expositions quotidiennes, dont l’environnement et
l’alimentation.
R É S U LTAT S : Nous avons inclus 219 participants (âge
moyen de 45 ans 6 10 ans ; 193 [88%] hommes). Des
symptômes respiratoires chroniques ont été rapportés
par 98 (45%) participants ; 46 (22%) avaient reçu un
traitement antituberculeux au moins deux fois ; la
prévalence du VIH était de 35 (16%). Des anomalies
ont été observées par spirométrie chez 146 (67%)
patients, et des anomalies à la radiographie pulmonaire
chez 177 (86%) patients. Un diagnostic de PTLD a été
posé chez 200 (91%) patients, dont la moitié avait une
PTLD cliniquement pertinente. La prévalence des
bronchites chroniques et des dyspnées (échelle
modifiée de Medical Research Council  grade 3)
était de 11% et 26%, respectivement. Un âge avancé,
de multiples épisodes de TB et certains indicateurs de
pauvreté étaient liés à une PTLD cliniquement
pertinente.
C O N C L U S I O N S : Nous avons observé un poids
sanitaire élevé dû à la PTLD chez les adultes ayant
récemment terminé leur traitement antituberculeux en
Tanzanie. Des approches efficaces doivent être
identifiées tant pour la prévention que pour la prise en
charge de cette maladie.
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